AC Immune price target lowered to $8 from $18 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered his price target for AC Immune to $8 to reflect the discontinuation of crenezumab in the valuation. However, despite this setback, the analyst still believes that the fundamental approach of AC Immune is “de-risking in itself” with multiple targets in multiple modalities. The company possesses one of the deepest pipelines in the neurodegenerative space, Fein tells investors in a research note. He reiterates a Buy rating on the shares.
https://thefly.com/landingPageNews.php?id=2858231